- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| So | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 24.02. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | 1 | ASX | ||
| 23.02. | VITA LIFE SCIENCES LIMITED: Dividend/Distribution - VLS | - | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 23.02. | VITA LIFE SCIENCES LIMITED: Preliminary Final Report | - | ASX | ||
| 20.01. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 14.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 14.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 12.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 08.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 08.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 03.01. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | 1 | ASX | ||
| 22.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 20.12.24 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | 1 | ASX | ||
| 18.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 17.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 16.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 15.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 15.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 11.12.24 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 6,550 | -1,65 % | Green Thumb Industries Reports Fourth Quarter and Full Year 2024 Results | CHICAGO and VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| INDIVA | 0,016 | -100,00 % | SNDL Inc.: SNDL Emerges as Canada's Leading Producer of Edibles with Indiva Acquisition | CALGARY, AB, Nov. 4, 2024 /CNW/ - SNDL Inc. (Nasdaq: SNDL) ("SNDL" or the "Company") announced today that, in the context of Indiva Limited's ("Indiva" and together... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 231,00 | -0,65 % | Alnylam Pharmaceuticals CEO Yvonne Greenstreet verkauft Aktien im Wert von 700.893 US-Dollar | ||
| CASSAVA SCIENCES | 2,469 | +4,13 % | Cassava Sciences, Inc.: Cassava Sciences Reports 2024 Financial Results and Provides Business Update | Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,794 | +3,25 % | Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata | SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA... ► Artikel lesen | |
| ADASTRA | 0,196 | -0,51 % | Adastra Holdings Ltd.: Adastra Holdings Announces New Director | Langley, British Columbia--(Newsfile Corp. - March 3, 2025) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 17,335 | +0,03 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,184 | +7,44 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL | - Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,360 | +0,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc: Molecule amends, settles, converts debentures | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA LR23: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUMINUS WELLNESS... ► Artikel lesen | |
| ZELIRA THERAPEUTICS | 0,278 | +4,51 % | ZELIRA THERAPEUTICS LIMITED: Appendix 4D & FY25 Interim Financial Report | ||
| OPUS GENETICS | 1,018 | +8,53 % | Opus Genetics gets FDA Fast Track designation for Phentolamine Ophthalmic Solution | ||
| SOLIGENIX | 2,210 | 0,00 % | SOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 57,50 | +2,68 % | ANI Pharmaceuticals Receives FDA Approval For Purified Cortrophin Gel Prefilled Syringe | WASHINGTON (dpa-AFX) - ANI Pharmaceuticals Inc. (ANIP) announced that the U.S. Food and Drug Administration approved Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.
